Enterprise Therapeutics
PrivateLast Round
Series B
Extension
Jan 30, 2024
Total Funding Raised
$87.1M
Company Overview
Enterprise Therapeutics is a biopharmaceutical company that discovers and develops novel therapies for the treatment of respiratory diseases such as cystic fibrosis, COPD, and severe asthma.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Enterprise Therapeutics Comparables
Compare Enterprise Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kither Biotech | 89% | |
| Parion Sciences | 87% | |
| Aer Therapeutics | 81% |
Enterprise Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jan 30, 2024 | ||||
| M&A | Oct 7, 2020 | ||||
| Grant | Oct 15, 2019 | ||||
| Series B | Apr 12, 2018 | ||||
| Grant | Apr 5, 2017 | ||||
VC Round | Nov 10, 2016 |
Key People
Founding team and executive leadership
Enterprise Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion | Series B Extension, Series B |
| IP Group | Series B Extension, Series B |
| Epidarex Capital | Series B Extension, Series B, Series A, VC Round |
| Cystic Fibrosis Trust | Grant |
| Versant Ventures | Series B Extension, Series B |
| Imperial Innovations | Series A, VC Round |
| Panakès Partners | Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 23, 2026
Monthly visitors increased 37% MoM, reaching 1.2K.
- Jan 30, 2024
$33M round led by Panakès Partners.
Enterprise Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Enterprise Therapeutics's valuation, stock price, and market status.
Is Enterprise Therapeutics a public or private company?
Enterprise Therapeutics is a private company.
What is the current stock price of Enterprise Therapeutics?
Enterprise Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Enterprise Therapeutics worth (valuation)?
Valuation information for Enterprise Therapeutics is not publicly available.
Can I buy Enterprise Therapeutics stock?
Enterprise Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Enterprise Therapeutics's last funding round?
Enterprise Therapeutics's most recent funding round was Series B Extension on January 30, 2024.
Who are the main investors in Enterprise Therapeutics?
Key investors in Enterprise Therapeutics include Versant Ventures, Cystic Fibrosis Foundation.
Will Enterprise Therapeutics IPO soon?
No public IPO plans have been announced for Enterprise Therapeutics.
How can I track Enterprise Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Enterprise Therapeutics's secondary market activity and sign up for updates.